anticipates strong growth in its Contract Research, Development and Manufacturing Organization (CRDMO) segment, forecasting a compound annual growth rate (CAGR) of approximately 19% for CRDMO sales over fiscal years 2026 to 2028. This projection is based on favorable market conditions and increasing demand in the CRDMO sector. The company aims to strengthen its position in the pharmaceutical outsourcing market through this strategic focus. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.